Drugs

Sitagliptin (marketed as Januvia and Janumet) Information

Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 


To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program and complete a form using the information at the bottom of the page.

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 07/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.